WO2007148092A3 - In vitro protein expression process comprising cκ fusion molecules - Google Patents

In vitro protein expression process comprising cκ fusion molecules Download PDF

Info

Publication number
WO2007148092A3
WO2007148092A3 PCT/GB2007/002309 GB2007002309W WO2007148092A3 WO 2007148092 A3 WO2007148092 A3 WO 2007148092A3 GB 2007002309 W GB2007002309 W GB 2007002309W WO 2007148092 A3 WO2007148092 A3 WO 2007148092A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein expression
vitro protein
expression process
fusion molecules
gene encoding
Prior art date
Application number
PCT/GB2007/002309
Other languages
French (fr)
Other versions
WO2007148092A8 (en
WO2007148092A2 (en
Inventor
Mingyue He
Michael John Taussig
Original Assignee
Babraham Inst
Mingyue He
Michael John Taussig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Babraham Inst, Mingyue He, Michael John Taussig filed Critical Babraham Inst
Priority to GB0822625A priority Critical patent/GB2452201A/en
Priority to EP07733308A priority patent/EP2029764A2/en
Publication of WO2007148092A2 publication Critical patent/WO2007148092A2/en
Publication of WO2007148092A3 publication Critical patent/WO2007148092A3/en
Publication of WO2007148092A8 publication Critical patent/WO2007148092A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

The invention relates to an in vitro protein expression process comprising preparation of a nucleic acid molecule which comprises a fusion of a gene encoding a target protein and a gene encoding an immunoglobulin Κ light chain constant domain (CΚ) followed by cell-free protein expression. The invention also relates to proteins expressed by said process and to a composition and kit for performing said in vitro protein expression process.
PCT/GB2007/002309 2006-06-21 2007-06-21 In vitro protein expression process comprising cκ fusion molecules WO2007148092A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB0822625A GB2452201A (en) 2006-06-21 2007-06-21 In vitro protein expression process comprising Ck fusion molecules
EP07733308A EP2029764A2 (en) 2006-06-21 2007-06-21 In vitro protein expression process comprising c fusion molecules

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0612223.8 2006-06-21
GB0612223A GB0612223D0 (en) 2006-06-21 2006-06-21 Ck fusion molecules

Publications (3)

Publication Number Publication Date
WO2007148092A2 WO2007148092A2 (en) 2007-12-27
WO2007148092A3 true WO2007148092A3 (en) 2008-02-07
WO2007148092A8 WO2007148092A8 (en) 2009-07-16

Family

ID=36803566

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/002309 WO2007148092A2 (en) 2006-06-21 2007-06-21 In vitro protein expression process comprising cκ fusion molecules

Country Status (3)

Country Link
EP (1) EP2029764A2 (en)
GB (2) GB0612223D0 (en)
WO (1) WO2007148092A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9937239B2 (en) 2014-05-21 2018-04-10 The Johns Hopkins University Preservation and reconstitution of cell-free protein expression systems

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0505908A1 (en) * 1991-03-27 1992-09-30 F. Hoffmann-La Roche Ag Chimaeric polypeptides
WO2005087810A2 (en) * 2004-03-08 2005-09-22 Zymogenetics, Inc. Dimeric fusion proteins and materials and methods for producing them

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0505908A1 (en) * 1991-03-27 1992-09-30 F. Hoffmann-La Roche Ag Chimaeric polypeptides
WO2005087810A2 (en) * 2004-03-08 2005-09-22 Zymogenetics, Inc. Dimeric fusion proteins and materials and methods for producing them

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BURSTEIN Y ET AL: "INDEPENDENT EXPRESSION OF THE GENE CODING FOR THE CONSTANT DOMAIN OF IMMUNO GLOBULIN LIGHT CHAIN EVIDENCE FROM SEQUENCE ANALYSES OF THE PRECURSOR OF THE CONSTANT REGION POLY PEPTIDE", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 74, no. 8, 1977, pages 3157 - 3161, XP002460062, ISSN: 0027-8424 *
CHEN HAIQIN ET AL: "Efficient production of a soluble fusion protein containing human beta-defensin-2 in E. coli cell-free system", JOURNAL OF BIOTECHNOLOGY, vol. 115, no. 3, 9 February 2005 (2005-02-09), pages 307 - 315, XP002460065, ISSN: 0168-1656 *
HE ET AL: "Antibody-ribosome-mRNA (ARM) complexes as efficient selection particles for in vitro display and evolution of antibody combining sites", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 25, no. 24, 15 December 1997 (1997-12-15), pages 5132 - 5134, XP002079231, ISSN: 0305-1048 *
HE M ET AL: "Single step generation of protein arrays from DNA by cell-free expression and in situ immobilisation (PISA method).", NUCLEIC ACIDS RESEARCH 1 AUG 2001, vol. 29, no. 15, 1 August 2001 (2001-08-01), pages E73 - E73, XP002460061, ISSN: 1362-4962 *
PALMER ELIZABETH ET AL: "Enhanced cell-free protein expression by fusion with immunoglobulin C kappa domain", PROTEIN SCIENCE, vol. 15, no. 12, December 2006 (2006-12-01), pages 2842 - 2846, XP008086103, ISSN: 0961-8368 *
SON JEONG-MI ET AL: "Enhancing the efficiency of cell-free protein synthesis through the polymerase-chain-reaction-based addition of a translation enhancer sequence and the in situ removal of the extra amino acid residues", ANALYTICAL BIOCHEMISTRY, vol. 351, no. 2, April 2006 (2006-04-01), pages 187 - 192, XP002460063, ISSN: 0003-2697 *
YANG JUNHAO ET AL: "Rapid expression of vaccine proteins for B-cell lymphoma in a cell-free system", BIOTECHNOLOGY AND BIOENGINEERING, vol. 89, no. 5, 5 March 2005 (2005-03-05), pages 503 - 511, XP002460064, ISSN: 0006-3592 *

Also Published As

Publication number Publication date
WO2007148092A8 (en) 2009-07-16
GB0612223D0 (en) 2006-08-02
GB0822625D0 (en) 2009-01-21
EP2029764A2 (en) 2009-03-04
WO2007148092A2 (en) 2007-12-27
GB2452201A (en) 2009-02-25

Similar Documents

Publication Publication Date Title
WO2008140582A3 (en) Production of anti-microbial peptides
DK1716178T3 (en) Less immunogenic binding molecules
WO2008098100A3 (en) Detection of molecule proximity
WO2008074867A3 (en) Anti-fc-receptor single domain antibodies (nanobodies-tm) and therapeutic use
WO2006131928A3 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
WO2008132568A3 (en) Fusion proteins binding to growth factors
WO2007070432A3 (en) Binding proteins specific for insulin-like growth factors and uses thereof
WO2008033413A3 (en) Albumin fusion proteins
WO2007146038A3 (en) Albumin fusion proteins
WO2010129304A3 (en) Method for making heteromultimeric molecules
WO2006034332A3 (en) In vivo incorporation of alkynyl amino acids into proteins in eubacteria
IL209350A0 (en) Anti -a?? globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
WO2009026393A3 (en) Amino acid substituted molecules
EA200700917A1 (en) REFOLDING METHOD FOR RECOMBINANT ANTIBODIES
WO2008048545A3 (en) Molecules with reduced half-lives, compositions and uses thereof
WO2006119107A3 (en) Sclerostin binding agents
WO2006119062A3 (en) Sclerostin epitopes
WO2009105670A3 (en) Substrates for multiplexed assays and uses thereof
EP2395091A3 (en) Plants having enhanced yield-related traits and a method for making the same
WO2008143679A9 (en) Nucleic acids and proteins and methods for making and using them
WO2006068953A3 (en) Antibodies directed to angiopoietin-2 and uses thereof
WO2005116237A3 (en) Site specific incorporation of heavy atom-containing unnatural amino acids into proteins for crystal structure determination
WO2007039903A3 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
WO2006113475A3 (en) Methods and compositions to modulate adhesion and stress tolerance in bacteria
WO2006068975A3 (en) Binding proteins specific for human matriptase

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07733308

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007733308

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 0822625

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20070621

WWE Wipo information: entry into national phase

Ref document number: 0822625.0

Country of ref document: GB

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU